SEC Form 4 · accession 0001104659-26-084438
Gain Therapeutics, Inc. · GANX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Claude Nicaise
Director
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 8:32 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001819411
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.68 | Jul 15, 2026 | A | 25,000 | A | — | Jul 15, 2036 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.